Sublobectomy versus lobectomy for long-term survival outcomes of early-stage non-small cell lung cancer with a tumor size ≤2 cm accompanied by visceral pleural invasion: a SEER population-based study

Yu, Yue; Huang, Run; Wang, Pei; Wang, Suyu; Ling, Xinyu; Zhang, Peng; Yu, Jingwen; Wang, Jun; Wang, Zhinong

doi:10.21037/jtd.2019.12.121

Cited by 24 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, anatomical surgical resection and mediastinal lymph node dissection are the most effective methods for treatment of early stage LUAC patients, and the main surgical procedures are lobectomy and sub-lobectomy ( Lin et al, 2020 ; Yu et al, 2020 ). Advanced-stage LUAC covers a variety of disease manifestations and has an equally complex range of multimodal treatment options, including systemic and local therapies (chemotherapy, radiation therapy, etc.)…”

Section: Introductionmentioning

confidence: 99%

Prognostic Signature for Lung Adenocarcinoma Patients Based on Cell-Cycle-Related Genes

Jiang

Liao

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

ObjectiveTo screen lung adenocarcinoma (LUAC)-specific cell-cycle-related genes (CCRGs) and develop a prognostic signature for patients with LUAC.MethodsThe GSE68465, GSE42127, and GSE30219 data sets were downloaded from the GEO database. Single-sample gene set enrichment analysis was used to calculate the cell cycle enrichment of each sample in GSE68465 to identify CCRGs in LUAC. The differential CCRGs compared with LUAC data from The Cancer Genome Atlas were determined. The genetic data from GSE68465 were divided into an internal training group and a test group at a ratio of 1:1, and GSE42127 and GSE30219 were defined as external test groups. In addition, we combined LASSO (least absolute shrinkage and selection operator) and Cox regression analysis with the clinical information of the internal training group to construct a CCRG risk scoring model. Samples were divided into high- and low-risk groups according to the resulting risk values, and internal and external test sets were used to prove the validity of the signature. A nomogram evaluation model was used to predict prognosis. The CPTAC and HPA databases were chosen to verify the protein expression of CCRGs.ResultsWe identified 10 LUAC-specific CCRGs (PKMYT1, ETF1, ECT2, BUB1B, RECQL4, TFRC, COCH, TUBB2B, PITX1, and CDC6) and constructed a model using the internal training group. Based on this model, LUAC patients were divided into high- and low-risk groups for further validation. Time-dependent receiver operating characteristic and Cox regression analyses suggested that the signature could precisely predict the prognosis of LUAC patients. Results obtained with CPTAC, HPA, and IHC supported significant dysregulation of these CCRGs in LUAC tissues.ConclusionThis prognostic prediction signature based on CCRGs could help to evaluate the prognosis of LUAC patients. The 10 LUAC-specific CCRGs could be used as prognostic markers of LUAC.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic Signature for Lung Adenocarcinoma Patients Based on Cell-Cycle-Related Genes

Jiang

Liao

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Segmentectomy is an anatomical resection with extensive lymph node dissection, while wedge resection removes the lung tumor and normal lung parenchyma from the margin surrounding the lung (16). Sublobectomy is preferred for tumors ≤2 cm combined with adenocarcinoma in situ, ≥50% ground-glass appearance on CT, or a long doubling radiologic surveillance time (≥400 days) (17).…”

Section: Introductionmentioning

confidence: 99%

Lobectomy vs. sublobectomy for stage I non-small-cell lung cancer: a meta-analysis

Wang

Xue

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: Although lobectomy is widely regarded as the treatment of choice for early-stage nonsmall-cell lung cancer (NSCLC), sublobectomy (segmentectomy and wedge resection) has emerged as an alternative modality over the years. Only a handful of studies has compared the treatment effects of these two surgical interventions. This study aimed to analyze the treatment effects between lobectomy and sublobectomy on the survival outcomes of patients with stage I NSCLC systematically.Methods: PubMed, Embase, and the Cochrane Library were systematically searched from their inception up to February 2019 for studies that compared the survival outcomes of lobectomy and sublobectomy.Studies that reported the diagnosis of stage I NSCLC by imaging or pathophysiology, lobectomy as intervention, sublobectomy as control, and overall survival (OS) and disease-free survival (DFS) as outcomes were included. The mean OS and DFS rates were calculated using the fixed-effects model.Results: A total of 12 studies that included 4,373 patients with stage I NSCLC were included in the metaanalysis. The patients who underwent lobectomy showed a significant improvement in OS than those who underwent sublobectomy (P=0.025). These results differed when stratified by publication year (before 2010 and after 2010), study design (prospective and retrospective), country (Eastern and Western), control (segmentectomy and wedge), and study quality (high and low), but no significant differences were observed in DFS. These results were not altered in the sensitivity and subgroup analyses.Conclusions: Stage I NSCLC patients who undergo sublobectomy display poor OS, whereas the DFS is similar for both methods.

show abstract

“…According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline in Oncology for NSCLC, a sub-lobar resection can be performed in patients with a tumor size ≤2 cm combined with adenocarcinoma in situ (AIS) histology, ≥50% groundglass appearance on CT or a long doubling radiologic surveillance time (≥400 days) (17).…”

Section: Surgical Approachmentioning

confidence: 99%

“…Yu et al analyzed a cohort of 1,386 patients with NSCLC less than 2 cm in size and VPI; the analysis shows that patients treated with lobectomy had better OS and DFS than those who underwent sublobectomy (17). Several studies have shown the ability of VPI to cause malignant pleural effusions and higher mediastinal lymph node metastases, therefore surgical resection should also include extensive lymph node dissection in order to obtain better staging.…”

Section: Surgical Approachmentioning

confidence: 99%

Non-small-cell lung cancer involving the pleura: a narrative review on the diagnostic and therapeutic pathway

Gonfiotti¹,

Gatteschi²,

Salvicchi³

et al. 2021

Curr Chall Thorac Surg

View full text Add to dashboard Cite

Visceral pleural invasion (VPI) is considered a challenging topic in the management of patients with non-small-cell lung cancer (NSCLC) since it has been incorporated into the last edition of tumor, node, metastasis (TNM) staging as a size independent T2 factor. VPI presents adverse outcomes and poorer prognosis, with higher rate of mediastinal lymph node metastases and malignant pleural effusion. In literature few studies investigated it, therefore there is still debate on the global management of these patients, from the preoperative staging to the optimal surgical procedure and the postoperative follow-up or the need of adjuvant chemotherapy. Our work is a narrative review taking into consideration the most recent and relevant articles concerning VPI and NSCLC. We have summarized the most appropriate diagnostic pathway, surgical approach and post-operative management in order to give these patients the best therapeutic option. The preoperatively prediction of pleural invasion is still too weak to ensure a preoperative upstaging. On the other hand, lobectomy with adequate lymph node dissection seems to be the most appropriate therapeutic option in these patients. Furthermore, there is no evidence of the usefulness of adjuvant chemotherapy and the lack of clinical trials leads clinicians to evaluate case-by-case the global management of these patients.

show abstract

Sublobectomy versus lobectomy for long-term survival outcomes of early-stage non-small cell lung cancer with a tumor size ≤2 cm accompanied by visceral pleural invasion: a SEER population-based study

Cited by 24 publications

References 39 publications

Prognostic Signature for Lung Adenocarcinoma Patients Based on Cell-Cycle-Related Genes

Prognostic Signature for Lung Adenocarcinoma Patients Based on Cell-Cycle-Related Genes

Lobectomy vs. sublobectomy for stage I non-small-cell lung cancer: a meta-analysis

Non-small-cell lung cancer involving the pleura: a narrative review on the diagnostic and therapeutic pathway

Contact Info

Product

Resources

About